Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment news

Show

From To
Vosevi safe, effective in ‘triple-infected’ patients with HCV, HBV, HIV

The direct-acting antiviral Vosevi demonstrated an average sustained virologic response rate of 87% among patients who were “triple-infected” with hepatitis C genotype 3, hepatitis B and HIV, as presented at the American College of Gastroenterology Annual Meeting.

Published
15 October 2018
From
Healio
Hepatitis C elimination in people living with HIV in the UK is feasible by 2021, British HIV Association says

Hepatitis C co-infection can be eliminated in people living with HIV in the United Kingdom by 2021, the British HIV Association (BHIVA) said today. “The UK can be

Published
10 October 2018
By
Keith Alcorn
Anti-virals cure up to 98% of hepatitis C patients since 2014

The figures from the national treatment registry for Irish hepatitis C patients represent “a triumph of science”, Dr Diarmuid Houlihan, a hepatologist at St Vincent’s University Hospital told a conference in Dublin on Monday.

Published
09 October 2018
From
Irish Times
Meta-analysis shows hepatitis C treatment is highly effective for drug users

Direct-acting antiviral treatment is highly effective at curing hepatitis C in people who inject drugs and in people receiving opioid substitution therapy (OST), a systematic

Published
28 September 2018
By
Keith Alcorn
What It Means for Gilead to Launch Its Own Generics for Hepatitis C Treatments

There is one fairly new effort for drug companies to mitigate the threat of generic drugs and for biotech companies to mitigate the threat of biosimilars. They can just launch their own. Several large drug and biotech companies have done so in recent years, and this is what is being seen at Gilead Sciences Inc.

Published
25 September 2018
From
24/7 Wall St.
Gilead to launch generic versions of its hepatitis drugs

Gilead Sciences Inc said on Monday it plans to launch generic versions of its hepatitis C drugs in the United States, at a time when regulators are looking to lower healthcare costs.

Published
25 September 2018
From
Reuters
Brazil court strips Gilead hepatitis drug patent, politician says

A Brazilian court has stripped the patent protection of a Gilead Sciences Inc big-selling hepatitis C treatment in Brazil, paving the way for cheaper generics, a presidential candidate who pushed for the move said on Monday.

Published
25 September 2018
From
Reuters
Overwhelming evidence shows hepatitis C treatment effective for people who inject drugs

Researchers are calling on an end to discriminatory health and illicit drugs policies, based on overwhelming evidence that new hepatitis C therapies are effective at curing the virus in people who inject drugs.

Published
21 September 2018
From
EurekAlert
EPO Upholds Gilead Patent On Hep C Medicines, But In Amended Form

The European Patent Office (EPO) on 13 September ruled in favour of pharmaceutical company Gilead and maintained the company’s patent on hepatitis C drug sofosbuvir. The patent, however, is maintained in an amended form. Civil society involved in the case expressed dismay over the outcome and its potential effect on European drug prices.

Published
16 September 2018
From
Intellectual Property Watch
Groups Call for End to Gilead’s Unwarranted Hepatitis C Drug Monopoly in Europe

This week in Munich, the European Patent Office (EPO) will hear a legal challenge filed by groups in 17 countries against an unmerited patent that allows US-based pharmaceutical corporation Gilead Sciences to charge exorbitant prices in Europe for the key hepatitis C drug sofosbuvir.

Published
11 September 2018
From
MSF press release
← First12345...101Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.